Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The present invention relates to novel biomarkers for preeclampsia, and to uses of the novel biomarkers. Preeclampsia is a disorder of pregnancy characterized by pregnancy-induced hypertension and proteinuria, which can lead to eclampsia (convulsions), and other serious maternal and/or foetal complications. Preeclampsia is originated in early gestation from the failure of implantation mechanisms and/or placental development, and is thus closely related to complications of pregnancy in early gestation such as including but not limited to implantation failure, and threatened and spontaneous miscarriage. Preeclampsia affects approximately 5-7% of pregnant women (approximately 8,370,000 pregnant women worldwide per year) and is a major cause of maternal and perinatal mortality. Furthermore, women with preeclampsia have an 8-fold higher risk of cardiovascular death later in their 15 life, and offspring born from pregnancies affected by preeclampsia have an increased risk of metabolic and cardiovascular disease and mortality later in life. In addition to the medical complications suffered by mothers and risks to their children, preeclampsia is also a huge financial burden to healthcare systems worldwide. We have provided a method of determining the preeclampsia status of a pregnant subject, comprising: (a) providing a biological sample obtained from the subject; and (b) determining the presence or absence, and/or level, of one or more of 5 Type XVII collagen alpha 1, leptin, neprilysin, Filamin B and Scavenger receptor class B member 1 in the biological sample

Type

Patent

Publication Date

12/03/2020

Addresses

Manu Vatish, University of Oxford, Oxford, United Kingdom